Analyst Price Targets — XFOR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 10, 2026 10:22 am | — | Wells Fargo | $11.00 | $3.96 | TheFly | X4 Pharmaceuticals initiated with an Overweight at Wells Fargo |
| June 2, 2026 10:22 am | Thomas Smith | Leerink Partners | $12.00 | $4.11 | TheFly | X4 Pharmaceuticals initiated with an Outperform at Leerink |
| March 9, 2026 10:45 am | — | Guggenheim | $12.00 | $4.15 | TheFly | X4 Pharmaceuticals initiated with a Buy at Guggenheim |
| December 5, 2025 11:37 am | James Condulis | Stifel Nicolaus | $10.00 | $3.80 | TheFly | X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel |
| November 5, 2025 5:17 pm | Stephen Willey | Stifel Nicolaus | $7.50 | $3.60 | StreetInsider | X4 Pharmaceuticals (XFOR) PT Lowered to $7.50 at Stifel |
| August 29, 2025 11:57 am | Stephen Willey | Stifel Nicolaus | $9.00 | $3.87 | TheFly | X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel |
| August 13, 2025 10:12 am | Swayampakula Ramakanth | H.C. Wainwright | $3.50 | $2.58 | TheFly | X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright |
| December 22, 2022 6:43 am | — | Cantor Fitzgerald | $3.00 | $0.85 | Benzinga | Cantor Fitzgerald Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $3 |
| December 11, 2022 5:05 pm | Edward Tenthoff | Piper Sandler | $3.00 | $0.93 | TheFly | X4 Pharmaceuticals initiated with an Overweight at Piper Sandler |
| November 30, 2022 6:30 am | — | H.C. Wainwright | $5.00 | $1.85 | Benzinga | HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5 |
Latest News for XFOR
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the…
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company's Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee.
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the…
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals' website under the Investors section: Events…
X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XFOR.
U.S. House Trading
No House trades found for XFOR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.